Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 131.58 M
The data is delayed by 15 minutes.
ANTH is in the long-term down -100% below S&P in 7 years.
Description: Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. It is developing blisibimod, a Phase III product candidate that targets elevated levels of B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. The company was founded in 2004 and is headquartered in Hayward, California.
|Shares Outstanding||40.99 M||EPS||-12.51||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-0.15|
|P/E To EPS Growth||P/S||P/BV||3.75||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-67.36%||ROE||-83.58%||ROI|
|Current Ratio||6.17||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.2|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||45.63 M||Cash From Investing Activities||-10 K||Cash From Operating Activities||-6.61 M||Gross Profit|
|Net Profit||-7.66 M||Operating Profit||-7.66 M||Total Assets||43.57 M||Total Current Assets||43.16 M|
|Total Current Liabilities||6.99 M||Total Debt||Total Liabilities||8.46 M||Total Revenue||240 K|
|High 52 week||2.7||Low 52 week||0.03||Last close||0.08||Last change||-10.81%|
|RSI||31.12||Average true range||0.02||Beta||1.76||Volume||515.23 K|
|Simple moving average 20 days||-18.17%||Simple moving average 50 days||-20.09%||Simple moving average 200 days||-90.29%|
|Performance Week||-20.95%||Performance Month||-24.14%||Performance Quart||11.09%||Performance Half||-97.2%|
|Performance Year||-94.93%||Performance Year-to-date||188.85%||Volatility daily||5.67%||Volatility weekly||12.69%|
|Volatility monthly||26%||Volatility yearly||90.07%||Relative Volume||61.67%||Average Volume||42.94 K|
|New High||New Low|
2018-12-10 14:31:46 | Last-minute tips for health coverage before Dec. 15 deadline
2018-08-31 07:40:00 | Report: Developing Opportunities within Anthera Pharmaceuticals, NRG Energy, Antares Pharma, El Pollo Loco, Paychex, and Cinedigm — Future Expectations, Projections Moving into 2018
2018-06-29 07:10:00 | Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space
2018-06-27 15:12:40 | Anthera Pharma Stock Plunged 53% Today, ANTH Suspended Tomorrow
2018-06-04 14:42:21 | What You Must Know About Anthera Pharmaceuticals Inc’s NASDAQ:ANTH Market Risks
2018-05-24 16:11:22 | Breaking Down Anthera Pharmaceuticals Inc’s NASDAQ:ANTH Ownership Structure
2018-05-04 08:20:00 | New Research: Key Drivers of Growth for Global Medical REIT, DXP Enterprises, SJW, FTI Consulting, Anthera Pharmaceuticals, and Alexandria Real Estate Equities — Factors of Influence, Major Initiatives and Sustained Production
2018-04-10 10:07:16 | Breakeven On The Horizon For Anthera Pharmaceuticals Inc NASDAQ:ANTH
2018-03-23 08:48:28 | Did Anthera Pharmaceuticals Inc’s NASDAQ:ANTH Recent Earnings Growth Beat The Trend?
2018-03-19 07:30:00 | Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight Medical Products, Eclipse Resources, and Aircastle with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
2018-03-12 17:55:07 | East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails
2018-03-12 17:38:05 | East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails
2018-03-12 08:47:47 | Anthera Pharmaceuticals' stock plunges toward record low after failed drug trial
2018-03-07 08:30:00 | Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference
2018-03-06 14:45:00 | Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria
2018-03-05 11:02:20 | Best Growth Stock Picks
2018-02-26 09:00:02 | Implied Volatility Surging for Anthera Pharmaceuticals ANTH Stock Options
2018-02-05 08:30:00 | Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
2018-01-31 10:34:03 | Will Bristol-Myers' BMY Q4 Earnings Exceed Expectations?
2018-01-30 08:26:01 | What's in Store for Cardinal Health CAH in Q2 Earnings?
2018-01-25 16:30:00 | Anthera Receives Positive Nasdaq Listing Determination
2018-01-23 10:45:03 | Anthera's Sollpura Strong on Positive Futility in Phase III
2018-01-23 08:57:01 | Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks
2018-01-17 08:10:00 | Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming Developments
2018-01-08 17:54:10 | Ultragenyx Announces Interim Data from Early Stage Study
2018-01-08 08:30:00 | Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
2017-11-29 15:37:09 | Want To Invest In Anthera Pharmaceuticals Inc ANTH? Here’s How It Performed Lately
2017-11-25 11:02:22 | Best Growth Stocks To Buy
2017-11-06 11:52:09 | Who Are The Major Shareholders Of Anthera Pharmaceuticals Inc ANTH?
2017-11-06 08:43:21 | Anthera reports 3Q loss
2017-10-24 08:30:00 | Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering